Works matching IS 15233790 AND DT 2014 AND VI 16 AND IP 2
Results: 7
Etirinotecan Pegol: Development of a Novel Conjugated Topoisomerase I Inhibitor.
- Published in:
- Current Oncology Reports, 2014, v. 16, n. 2, p. 1, doi. 10.1007/s11912-013-0367-8
- By:
- Publication type:
- Article
Endoglin for Targeted Cancer Treatment.
- Published in:
- Current Oncology Reports, 2014, v. 16, n. 2, p. 1, doi. 10.1007/s11912-013-0365-x
- By:
- Publication type:
- Article
Timing of Determining Axillary Lymph Node Status When Neoadjuvant Chemotherapy is Used.
- Published in:
- Current Oncology Reports, 2014, v. 16, n. 2, p. 1, doi. 10.1007/s11912-013-0364-y
- By:
- Publication type:
- Article
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin.
- Published in:
- Current Oncology Reports, 2014, v. 16, n. 2, p. 1, doi. 10.1007/s11912-013-0370-0
- By:
- Publication type:
- Article
Aflibercept-a Decoy VEGF Receptor.
- Published in:
- Current Oncology Reports, 2014, v. 16, n. 2, p. 1, doi. 10.1007/s11912-013-0368-7
- By:
- Publication type:
- Article
Endoscopic Resection of Sinonasal Cancers.
- Published in:
- Current Oncology Reports, 2014, v. 16, n. 2, p. 1, doi. 10.1007/s11912-013-0369-6
- By:
- Publication type:
- Article
Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?
- Published in:
- Current Oncology Reports, 2014, v. 16, n. 2, p. 1, doi. 10.1007/s11912-013-0366-9
- By:
- Publication type:
- Article